Ticker

CAMBRIDGE, Mass., July 02, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 3 newly-hired employees options to purchase an aggregate of 125,600 shares of Akebia's common stock on June 30, 2026. The options were granted as an inducement material to each employee entering into employment…

Vafseo® demonstrated a clinically meaningful safety outcome benefit in U.S. patients with anemia due to CKD on dialysis utilizing TIW dosing regimen Primary Investigator to stop trial on recommendation from Independent Data Monitoring Committee and Trial Steering Committee Interim analysis on primary endpoint replicated safety outcomes reported in the recently published win odds analysis of the INNO 2 VATE clinical…

CAMBRIDGE, Mass., June 10, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that a new patent has been granted and listed in the Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) and it has been notified of eligibility to extend the expiration of a…

Akebia Therapeutics NASDAQ: AKBA outlined its commercial priorities for Vafseo, the expected evolution of reimbursement after the TDAPA period and several renal-disease pipeline programs during a fireside chat at the Jefferies 2026 Global Healthcare Conference.

CAMBRIDGE, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted one newly-hired employee options to purchase an aggregate of 8,400 shares of Akebia's common stock on May 29, 2026. The options were granted as an inducement material to the employee entering into employment…